dendreon ranked highest in sales growth, page-3

Most of us including a very professionally organised team at Prima know of Dendreon's successful Provenge treatment for prostate cancer and we also respect that Prima's CVac technology can not touch Dendreon's orphan drug status for the treatment of this form of cancer for 7 years. However judging by this article released today it appears that Dendreon might not be aware of Prima's progress with Phase2b & 3 CVac trials

Should someone be telling them?

Dendreon also has research underway to extend its active cellular immunotherapy technology to treat patients with breast, ovarian, and colorectal solid tumors.

However, the two clinical trials in this area just finished Phase 1. Phase 2 and 3 clinical trials take several years, and so no revenue from this research can be forecast for at least 5 years. With only Provenge to provide growth in revenue for the next 5 years, Dendreon is simply too expensive for wise investors.